Pfizer’s buyout bid for Metsera was deemed inferior to the latest bid from Novo Nordisk, putting the original agreement in doubt despite legal efforts to enforce it.

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID vaccine sales. Read more here.

Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer.

Pfizer beat earnings expectations decisively this morning, with shares of PFE gapping up more than 12% in pre-market trading.

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage MASH combo.

The past few months have been pivotal for Pfizer Inc. We are really excited about our future and confident that we are in a strong position to continue delivering value for patients and our shareholders.

Pfizer also has set its sights on becoming a giant in oncology, and to support this, completed the acquisition of Seagen in 2023. Two of Seagen's products in the most recent quarter delivered double-digit growth, and Seagen's technology and pipeline offer Pfizer the opportunity to further expand its oncology portfolio.

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.